GYRE THERAPEUTICS, INC. (GYRE) Guidance & Earnings Results
On 2026-08-07 GYRE THERAPEUTICS, INC. reaffirmed guidance: "$100.5-$111.0M…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GYREGYRE THERAPEUTICS, INC.Follow GYRE — free
—
Price chart with a free account
- Market cap
- 652.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 7 Aug 26 | Reaffirmed | $100.5-$111.0M · full year |
| 7 May 26 | Reaffirmed | FY2026 revenue guidance $100.5-$111.0M affirmed · full year |
| 12 Mar 26 | Reaffirmed | FY2026 revenue guidance $100.5-111.0M; FY2025 revenue $116.6M (within revised guidance range) · full year |
| 7 Nov 25 | Lowered | FY2025 revenue guidance cut to $115-118M from $118-128M · full year |
| 11 Aug 25 | Reaffirmed | FY25 revenue $118-128M · full year |
GYRE THERAPEUTICS, INC. — questions
- What guidance did GYRE THERAPEUTICS, INC. give?
- On 2026-08-07: "$100.5-$111.0M"
- When does GYRE THERAPEUTICS, INC. report earnings?
- GYRE THERAPEUTICS, INC.'s next earnings report is expected on 2026-11-18.
Every figure on this page comes from GYRE THERAPEUTICS, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.